Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
784.00    0.00 (0.00%)
Bid:
784.00
Ask:
790.00
Spread: 6.00 (0.765%)
Market Cap: £361.39m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Pre-close Trading Update and Acquisition

8 Dec 2017 07:00

RNS Number : 7434Y
Porvair PLC
08 December 2017
 

For immediate release 8 December 2017

 

 

Porvair PLC

 

Pre-close trading update and acquisition

 

Porvair plc ("Porvair", "the Group" or "the Company"), the specialist filtration and environmental technologies group, announces the following trading update and acquisition ahead of its close period for the year ended 30 November 2017.

Trading update

Revenue growth for the year ended 30 November 2017 was 6%. Underlying revenue(1) growth was 11% overall, with underlying revenue growth of 13% in the Microfiltration division and 1% in the Metals Filtration division. Earnings for the year are forecast to be ahead of management's expectations.

Net cash at the 30 November 2017 was £9.7 million (2016: £13.6 million), after capital and acquisition expenditure of approximately £11 million. Group order books for the start of the 2018 financial year are healthy. 

New divisional structure

Recognising the Group's growth in recent years, and as noted in the 2017 interim report, the Board will change the Group's management and reporting structure in 2018 to one that offers better management and market focus and greater investor clarity. The 2017 Report and Accounts will use the current two division structure, but will include proforma information for the new three new divisions, which will serve distinct markets: Aerospace & Industrial; Laboratory; and Molten Metals.

Acquisition

The new Laboratory division, which will focus on filtration and sample preparation products, acquired Rohasys B.V., a Dutch company, on 7 December 2017. This small acquisition brings robotic sample handling expertise to the division, which will enhance the Group's growing bioscience sample preparation capabilities.

Date of preliminary announcement

Porvair will announce its preliminary results for the year ended 30 November 2017 on Monday 29 January 2018.

Market Abuse Regime

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation. Upon the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain.

Note (1) Underlying revenue: Revenue at constant currency excluding the impact of large projects.

 

For further information, please contact:

Porvair plc

 

01553 765 500

Ben Stocks, Chief Executive

 

 

Chris Tyler, Group Finance Director

 

 

Buchanan Communications

 

0207 466 5000

Charles Ryland / Steph Watson

 

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration, separation and environmental technologies businesses. Its products are used in a range of niche filtration and separation markets, and are derived from its expertise in the design and manufacture of filtration and separation systems. From the 2018 financial year it is organised into three divisions: Aerospace & Industrial; Laboratory; and Molten Metals.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBUNRBAAURAA
Date   Source Headline
1st Mar 20239:30 amRNSTotal Voting Rights
2nd Feb 20235:42 pmRNSGrant of LTSP awards
30th Jan 20237:00 amRNSResults for the year ended 30 November 2022
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSTrading Update, Notice of Results and Board Change
1st Dec 20224:00 pmRNSDirector/PDMR Shareholding
1st Dec 202210:00 amRNSTotal Voting Rights
29th Nov 20224:35 pmRNSPrice Monitoring Extension
1st Nov 20224:00 pmRNSBlock listing Interim Review
1st Nov 20227:00 amRNSTotal Voting Rights
27th Oct 20229:30 amRNSDirector declaration and resignation
12th Oct 20224:26 pmRNSDirector/PDMR Shareholding
5th Oct 20225:30 pmRNSHolding(s) in Company
5th Oct 20225:30 pmRNSHolding(s) in Company
4th Oct 20227:00 amRNSTrading Update-Ahead of Expectations
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
13th Sep 20227:00 amRNSNine Month Trading Update
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20226:05 pmRNSDirector/PDMR Shareholding
6th Sep 20224:40 pmRNSHolding(s) in Company
2nd Sep 20223:06 pmRNSHolding(s) in Company
10th Aug 20224:40 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
9th Aug 20224:36 pmRNSPrice Monitoring Extension
8th Jul 20227:00 amRNSDirector Declaration
5th Jul 20224:35 pmRNSPrice Monitoring Extension
4th Jul 20227:00 amRNSHalf Year Results 2022
30th Jun 20222:15 pmRNSDirector/PDMR Shareholding
29th Apr 20224:41 pmRNSSecond Price Monitoring Extn
29th Apr 20224:36 pmRNSPrice Monitoring Extension
28th Apr 20227:00 amRNSDirector/PDMR Shareholding
14th Apr 20221:42 pmRNSAGM resolutions
14th Apr 20227:00 amRNSAGM Trading Update
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20224:35 pmRNSPrice Monitoring Extension
28th Feb 20227:00 amRNSBlock listing Interim Review
28th Feb 20227:00 amRNSTotal Voting Rights
4th Feb 20223:00 pmRNSDirector/PDMR Shareholding
4th Feb 202212:20 pmRNSGrant of LTSP awards
3rd Feb 202211:27 amRNSDirector/PDMR Shareholding
31st Jan 20227:00 amRNSResults for the year ended 30 November 2021
14th Dec 202112:25 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.